Sanofi confirms 2020 outlook
Sanofi, a pharmaceutical group, announced that 1Q business net income rose 15.9% on year to 2.04 billion euros and business operating income increased 15.8% to 2.66 billion euros on net sales of 8.97 billion euros, up 6.9%
Share this:
Sanofi, a pharmaceutical group, announced that 1Q business net income rose 15.9% on year to 2.04 billion euros and business operating income increased 15.8% to 2.66 billion euros on net sales of 8.97 billion euros, up 6.9% (+6.6% at constant exchange rates). The company said it continues to expect business EPS to grow around 5% at constant exchange rates (+15.6% in 1Q).
Global healthcare stocks have recently outperformed the STOXX 600 in Europe. From a technical point of view, Sanofi remains in a short term bullish trend, within a bullish channel. The daily Relative Strength Index (RSI, 14) is bullish and not overbought. The stock price is trading above its 50DMA which started to flatten out. This may indicate an imminent consolidation move for the stock as prices are approaching from Feb 19th high at 95E.
Immediate support is set 86.6E near the 100DMA but the key short term support threshold is set at 80.7E. A break above 95E would open the way to a further rise towards 99E (upper Bollinger boundary on a weekly chart).
Source: GAIN Capital, TradingView
Sanofi, a pharmaceutical group, announced that 1Q business net income rose 15.9% on year to 2.04 billion euros and business operating income increased 15.8% to 2.66 billion euros on net sales of 8.97 billion euros, up 6.9% (+6.6% at constant exchange rates). The company said it continues to expect business EPS to grow around 5% at constant exchange rates (+15.6% in 1Q).
Global healthcare stocks have recently outperformed the STOXX 600 in Europe. From a technical point of view, Sanofi remains in a short term bullish trend, supported by a rising trend line. The daily Relative Strength Index (RSI, 14) is bullish and not overbought. The stock price is trading above its 50DMA which started to flatten out. This may indicate an imminent consolidation move for the stock as prices are approaching from Feb 19th high at 95E.
Immediate support is set 86.6E near the 100DMA but the key short term support threshold is set at 80.7E. A break above 95E would open the way to a further rise towards 99 (upper Bollinger boundary on a weekly chart).
Source: GAIN Capital, TradingView
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
GBP/USD, Dow Jones Forecast: Key Technical Scenarios to Watch
GBP/USD and the Dow Jones are approaching critical technical levels amid earning optimism, Fed rate hike expectations, US-Iran developments, and persistent geopolitical risks.
The U.S. Dollar Is Rising Again and Nasdaq Is Feeling It
Nasdaq, the U.S. Dollar Index and Federal Reserve expectations are driving market sentiment ahead of a pivotal FOMC meeting. Razan Hilal, StoneX Market Analyst, explains how rising expectations for a hawkish Federal Reserve, persistent U.S.-Iran tensions and key technical levels on the U.S. Dollar Index could influence currencies, equities and precious metals in the weeks ahead.
US Dollar and Nasdaq Forecast: Fed, Microsoft, Meta, and Iran Talks in Focus
The US Dollar Index (DXY) continues to hold above the 101.00 mark, reinforcing its bullish structure, while the Nasdaq remains capped below the 29,000 resistance and its June-July consolidation range, reflecting cautious risk appetite ahead of the Federal Reserve's policy decision and major earnings releases on Wednesday.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.